时间：2019-05-14 16:44 作者：admin 点击:次
On September 22, 2017, Zai Lab Limited(Nasdaq: ZLAB) announced the closing of its initial public offering of American depositary shares, which have been listed on the Nasdaq Global Market, raising gross proceeds of approximately US$172.5 million upon the underwriters full exercise of the over-allotment option. J.P. Morgan,CitigroupandLeerink Partnersacted as joint book-running managers for the offering.
Zai Lab is an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases.
Zhong Lun Law Firm acted as Zai Lab s PRC legal counsel in the offering. The legal team from Zhong Lun was led by Anthony Zhao, William Jia and Helen Cheng,and included Roy Zheng, Lindsay Zhang and Shuman Zhang, etc.